Notice of extraordinary general meeting in Coegin Pharma AB (publ)

The shareholders of Coegin Pharma AB, reg. no. 559078-0465, are hereby invited to attend the Extraordinary General Meeting on Wednesday, 22 July 2026 at 2:00 p.m. at Medicon Village, Scheeletorget 1, Lund.

Right to participate and notice of attendance
Shareholders who wish to participate in the general meeting must

• be registered as a shareholder in the share register maintained by Euroclear Sweden AB on Tuesday, 14 July 2026, and
• notify the Company of their intention to attend no later than Thursday, 16 July 2026, in writing to Coegin Pharma AB, c/o Medicon Village, SE-223 81 Lund, Sweden (mark the envelope "General Meeting 2026") or by email to info@coeginpharma.com. The notice of attendance shall state the shareholder's full name, personal identity number or company registration number, shareholding, address, daytime telephone number and, where applicable, details of any proxy or assistant (maximum two). Where applicable, the notice should be accompanied by powers of attorney, registration certificates and other authorization documents.

Nominee-registered shares
Shareholders whose shares are nominee-registered must, in order to be entitled to participate in the general meeting, contact their bank or nominee and request that their shares be temporarily registered in their own name in the share register maintained by Euroclear Sweden AB as of the record date on 14 July 2026. Such registration may be temporary (so-called voting rights registration). Voting rights registrations requested by shareholders in such time that the registration has been completed by the nominee no later than the second banking day after 14 July 2026 will be taken into account in the preparation of the share register.

Proxies and proxy forms
Shareholders who are not personally present at the general meeting may exercise their rights at the general meeting through a proxy appointed by a written, signed and dated power of attorney. A proxy form is available on the Company's website, www.coeginpharma.com. The proxy form may also be obtained from the Company and will be sent to shareholders who request it and provide their address. If the power of attorney is issued by a legal entity, a copy of the certificate of registration or equivalent authorization document for the legal entity shall be attached. A power of attorney may not be older than one year unless a longer period of validity is specified in the power of attorney, however not exceeding five years. In order to facilitate registration at the general meeting, powers of attorney, certificates of registration and other authorization documents should be received by the Company well in advance of the meeting.

Number of shares and votes
The total number of outstanding shares and votes in the Company at the time of this notice amounts to 28,591,254. The Company holds no treasury shares.

Proposed agenda

1. Opening of the meeting and election of a chairperson of the meeting.
2. Preparation and approval of the voting register.
3. Approval of the agenda.
4. Election of one or two persons to verify the minutes.
5. Determination of whether the meeting has been duly convened.
6. Resolution on a directed issue of units to subscribers covered by Chapter 16 of the Swedish Companies Act.
7. Closing of the meeting.

Proposed resolutions

Resolution on a directed issue of units to subscribers covered by Chapter 16 of the Swedish Companies Act (item 6)
The Board of Directors of Coegin Pharma AB (publ), reg. no. 559078-0465 (the "Company"), proposes that the general meeting resolves on a directed issue of not more than 1,072,631 units with deviation from the shareholders' pre-emption rights on the following terms and conditions.

1.  Each unit shall consist of two (2) newly issued shares and one (1) warrant of series 2026/2027 issued free of charge. Consequently, not more than 2,145,262 new shares and not more than 1,072,631 new warrants may be issued. The resolution entails that the Company's share capital may increase by not more than SEK 214,526.20 through the issue of shares. Furthermore, the resolution entails that the Company's share capital may increase by an additional maximum of SEK 107,263.10 upon full exercise of the warrants. Through the new issue, the Company will receive proceeds of not more than SEK 6,349,975.52.
   
   
2. The subscription price shall amount to SEK 5.92 per unit, corresponding to a subscription price of SEK 2.96 per share. The warrants shall be issued free of charge.
   
   The subscription price has been determined following negotiations with the subscribers (excluding the Board member and the CEO) and represents a discount of approximately 15 per cent compared to the volume-weighted average price of the Company's share during the ten (10) trading days preceding the date of determination of the proposal. In light of the challenging financing climate prevailing in the capital markets, the Board of Directors considers the subscription price to be on market terms and reflective of the demand for the Company's shares.
   
   
3. The right to subscribe for units shall, with deviation from the shareholders' pre-emption rights, vest in the following persons:

1. Any share premium shall be allocated to the unrestricted share premium reserve.
   
   
2. Subscription for units shall be made on a subscription list within seven (7) days from the date of the issue resolution. Payment for subscribed units shall be made in cash within the same period.
   
   
3. The Board of Directors shall be entitled to extend the subscription period and the payment period.
   
   
4. Allocation shall be resolved upon by the Board of Directors. Oversubscription is not permitted.
   
   
5. Subscription for shares by exercise of the warrants shall be made in accordance with the terms and conditions of the warrants during the period from 1 January 2027 up to and including 29 January 2027.
   
   
6. Each warrant shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to eighty (80) per cent of the volume-weighted average price of the Company's share during the last ten (10) trading days of 2026, however not lower than the quota value of the share and not higher than SEK 12.
   
   
7. The warrants shall otherwise be subject to the terms and conditions set out in the complete warrant terms.
   
   
8. Shares issued upon subscription shall carry entitlement to dividends from the first record date for dividends occurring after the subscription has been registered to such extent that the shares have been entered as interim shares in the Company's share register.
   
   
9. The Chief Executive Officer, or any person appointed by the Board of Directors, shall be authorized to make such minor adjustments to the resolution as may be required in connection with registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

Background and reasons for the deviation from the shareholders' pre-emption rights

As members of the Company's Board of Directors and management are included among the proposed subscribers, the issue is subject to the provisions of Chapter 16 of the Swedish Companies Act, the so-called Leo Act. Consequently, the Board of Directors has carefully considered the proposal.

The share issue is carried out for the purpose of strengthening the Company's liquidity and improving the Company's financial position in a time- and cost-efficient manner. Prior to proposing the issue, the Board of Directors has carefully examined and considered alternative financing options, including raising capital through a rights issue. However, following an overall assessment and careful consideration, the Board of Directors has concluded that a new share issue with deviation from the shareholders' pre-emption rights constitutes a more favourable alternative for the Company and its shareholders than a rights issue and that it is objectively in the interests of both the Company and its shareholders to carry out the issue. The Board of Directors has, among other things, taken the following factors into account.

A rights issue would have required significantly more time and resources than the proposed issue, inter alia due to the extensive work required to ensure such an offering. Furthermore, there is no guarantee that a rights issue would be fully subscribed. By reducing the time required, the Company gains greater flexibility to take advantage of short-term investment opportunities, while reducing its exposure to fluctuations in the stock market and benefiting from the current interest in the Company's share. The costs associated with the issue are also expected to be lower than those of a rights issue, not least because a rights issue, given the market volatility experienced during 2025 and 2026, would likely require extensive underwriting commitments from a guarantee consortium, which in turn would entail additional costs and/or dilution for shareholders depending on how such compensation would be structured.

The reason for directing the issue to existing shareholders and members of the Board of Directors and management is that these parties have expressed and demonstrated a long-term commitment to the Company, which in the Board of Directors' assessment creates security and stability for both the Company and its shareholders and contributes significant strategic and long-term value.

Majority requirements
For a valid resolution under item 6 above, the resolution must be supported by shareholders representing at least nine-tenths of both the votes cast and the shares represented at the Extraordinary General Meeting.

Documents and information at the meeting
Shareholders are reminded of their right to request information pursuant to Chapter 7, Section 32 of the Swedish Companies Act. All documents in accordance with the Swedish Companies Act (2005:551) will be available at the Company's offices in Lund and on the Company's website www.coeginpharma.com no later than three weeks prior to the meeting, and will be sent to shareholders who so request and provide their postal address.

Processing of personal data
For information on how your personal data is processed, please refer to the privacy policy available on Euroclear's website: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Coegin Pharma AB (publ) has its registered office in the municipality of Lund.

Lund, June 2026
Coegin Pharma AB (publ)
The Board of Directors

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. The company's flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company's own brand platform. In parallel, Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone.

With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.

Coegin Pharma's share is listed on the NGM Growth Market and dual-listed on Börse Stuttgart. The company is 

headquartered in Lund, Sweden. 

For more information, including company updates and social media links, visit coeginpharma.com

Attached files